Supporting FivepHusion’s World Improvement and Commercialization Technique
SYDNEY, Might 26, 2023 /PRNewswire/ — FivepHusion, a sophisticated clinical-stage biotechnology firm, right this moment introduced its collaboration with Treehill Companions, a New York-based strategic and monetary advisory agency specializing in healthcare trade transactions, and Syneos Well being® (Nasdaq: SYNH), a number one totally built-in biopharmaceutical options group, to develop and produce a novel, enhanced chemotherapeutic product to market.
Treehill Companions will help FivepHusion with built-in enterprise growth, operational, strategic and transactional experience. Syneos Well being will help FivepHusion’s built-in scientific growth and commercialization capabilities. This collaboration is designed to strategically and optimally progress growth and commercialization of FivepHusion’s enhanced chemotherapeutic formulation Deflexifol™ in international markets.
“It is a very thrilling time for FivepHusion. We’re at a vital stage in our progress technique. By collaborating with Treehill Companions and Syneos Well being, we consider we’re positioned to efficiently convey our growth work on Deflexifol™ to international markets, together with within the US, Europe and Asia,” mentioned Dr. Christian Toouli, CEO & Managing Director, FivepHusion. “This collaboration represents a novel working mannequin to the trade. By way of the mixed power and competency of three trade leaders, we intend to maximise our progress on the event of Deflexifol™ and shortly convey revolutionary oncology medicines to sufferers in want.”
“We’re excited to collaborate with FivepHusion and Treehill Companions to assist convey Deflexifol™ to sufferers,” mentioned Christian Tucat, Chief Enterprise Officer, Syneos Well being. “Leveraging our deep therapeutic and international experience, Syneos Well being is happy to contribute to accelerating the scientific growth and commercialization of this necessary new remedy.”
“This collaboration represents a brand new mannequin of built-in companies throughout disciplines, designed to permit US and non-US rising gamers to play a key position on the worldwide stage, and we’re proud to work alongside FivepHusion and Syneos Well being,” mentioned Ali Pashazadeh, Accomplice & Co-founder, Treehill Companions. “By merging the scientific prowess of our shoppers with the scientific and business experience of Syneos Well being and Treehill’s healthcare advisory and execution capabilities, we’re offering a novel ecosystem designed to assist corporations to flourish regardless of the present difficult market atmosphere.”
FivepHusion (www.fivephusion.com) is a sophisticated clinical-stage, globally centered biotechnology firm whose function is to optimize chemotherapy to enhance affected person remedy outcomes and high quality of life.
FivepHusion is creating Deflexifol™, a proprietary, novel, and optimized physiological pH formulation to co-administer the chemotherapeutic agent 5-fluorouracil (5-FU) and its biomodulator leucovorin (LV), a drug that enhances 5-FU anti-cancer exercise. These medicine are generally used globally to deal with varied strong tumors together with colorectal, pancreatic, gastric and breast cancers. Nevertheless, as a consequence of their chemical incompatibility, present formulations of 5-FU and LV undergo from limitations of their security, tolerability, effectiveness and pharmacological compatibility. These disadvantages contribute to restricted remedy response charges, disagreeable unwanted effects and toxicities, and a lowered high quality of life skilled by most cancers sufferers. Deflexifol™ has been designed to handle these limitations by way of co-administration of the 2 brokers with clinically demonstrated enhancements in security and tolerability and the potential to supply superior anti-tumor efficacy, higher high quality of life, and total enhanced scientific profit for most cancers sufferers.
FivepHusion is creating Deflexifol™ through the FDA 505(b)(2) and EMA Article 10b regulatory pathways as a bioequivalent, chemotherapy substitute of sub-optimal commonplace of care formulations of 5-FU and LV for the remedy of metastatic colorectal most cancers, and different tumors with a projected international incidence of higher than 6 million sufferers. Deflexifol™ can also be being developed as a brand new remedy for cancers with excessive unmet medical want, together with pediatric ependymoma; a uncommon and lethal mind most cancers which afflicts very younger kids.
Deflexifol™ is a trademark of FivepHusion.
About Syneos Well being
Syneos Well being® (Nasdaq: SYNH) is a number one totally built-in biopharmaceutical options group constructed to speed up buyer success. Syneos interprets distinctive scientific, medical affairs and business insights into outcomes to handle trendy market realities.
Syneos brings collectively a proficient workforce of execs, who work throughout greater than 110 nations, with a deep understanding of affected person and doctor behaviors and market dynamics. Collectively Syneos shares insights, makes use of the most recent applied sciences and applies superior enterprise practices to hurry clients’ supply of necessary therapies to sufferers.
Syneos Well being helps a various, equitable and inclusive tradition that cares for colleagues, clients, sufferers, communities and the atmosphere.
To study extra about how Syneos are Shortening the gap from lab to life®, go to syneoshealth.com or subscribe to our podcast.
About Treehill Companions
Treehill was based in 2014 and is led by companion and co-founder Ali Pashazadeh, who beforehand headed Blackstone’s healthcare advisory workforce and UBS’ European biotech protection.
Treehill helps shoppers within the healthcare trade all through the asset lifecycle, from buy-side acquisition and funding over worth construct and progress to sell-side disposal and divestment. Key areas of focus are the figuring out and executing of worth artistic transactions and their knitting into profitable company evolution methods.
In delivering its recommendation, the agency employs a multidisciplinary senior workforce with impeccable pedigree that contains medical docs/ MDs, scientists/ PhDs, CEOs of biotechs, senior executives from massive pharma, and skilled technique consultants and funding bankers. Companies supplied are centered across the “principal mentality” of the workforce, delivering actionable strategic and transaction recommendation that issues to CEOs, senior management, their stakeholders and buyers.
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/fivephusion-announces-strategic-collaboration-with-treehill-partners-and-syneos-health-301835410.html